Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals

Philip M. Grant,1 Douglas Kitch,2 Grace A. McComsey,3 Ann C. Collier,4 Susan L. Koletar,5 Kristine M. Erlandson,6 Michael T. Yin,7 Benedetta Bartali,4 Belinda Ha,8 Kathy Melbourne,2 and Todd T. Brown9

1Division of Infectious Diseases, Department of Medicine, Stanford University, Palo Alto, and 2Gilead Sciences, Foster City, California; 3Center for Biostatistics in AIDS Research, Harvard T. H. Chan School of Public Health, Boston, and 4New England Research Institute, Watertown, Massachusetts; 5Division of Infectious Diseases, Departments of Pediatrics and Medicine, Case Western Reserve University, Cleveland, and 6Division of Infectious Diseases, Department of Medicine, Ohio State University, Columbus; 7Division of Infectious Diseases, Department of Medicine, University of Washington, Seattle; 8Division of Infectious Diseases, Department of Medicine, Columbia University, New York, New York; 9Viv Health Care, Research Triangle, North Carolina; and 10Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Johns Hopkins University, Baltimore, Maryland

We compared adjusted bone mineral density (BMD) changes between human immunodeficiency virus (HIV)-infected individuals during the first approximately 7.5 years after antiretroviral therapy (ART) initiation and HIV-uninfected controls. HIV-infected individuals (n = 97) had significantly greater adjusted BMD decline than controls (n = 614) during the first 96 weeks of ART. Subsequently, the rate of BMD decline slowed in HIV-infected individuals but remained greater than the rate of decline in HIV-uninfected individuals at the lumbar spine but not at the hip. In HIV-infected individuals after 96 weeks, no HIV- or treatment-related characteristic was associated with BMD loss, but lower lean body mass was associated with greater BMD loss at both lumbar spine and hip.

Keywords. anti-HIV agents, administration and dosage, adverse effects; HIV infections, drug therapy/virology; bone density.

Low bone mineral density (BMD) occurs in 40%–90% of human immunodeficiency virus (HIV)-infected individuals [1]. The etiology of low BMD is multifactorial, with contributions from antiretroviral therapy (ART), HIV and its associated immune dysfunction, and traditional osteoporosis risk factors [2]. HIV-infected individuals have a 60% increased fracture risk as compared to uninfected individuals [3].

BMD loss is substantial during the first 2 years of ART, generally decreasing 2%–6% [4], although the loss may be less with some integrase inhibitor–containing regimens [5]. There are few studies on long-term BMD changes in ART-treated individuals. No study has compared long-term BMD changes in HIV-infected individuals initiating ART to changes in uninfected controls. This study’s aim is to compare long-term BMD change after ART initiation in a well-characterized HIV-infected study population to that observed in HIV-uninfected individuals.

METHODS

Participants and Study Procedures

ART-naive HIV-infected individuals in AIDS Clinical Trials Group (ACTG) A5202 were randomly assigned to receive atazanavir/ritonavir (ATV/r) or efavirenz (EFV) combined with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) or abacavir/lamivudine (ABC/3TC) during 2005–2007 [6]. Participants in the metabolic substudy, ACTG A5224s, underwent baseline and follow-up whole-body and site-specific dual-energy x-ray absorptiometry (DXA), with primary end points reported at 96 weeks after ART initiation [3].

In 2013–2014, we attempted to contact participants previously enrolled in ACTG A5224s. Study exclusion criteria included previous receipt of osteoporosis medications, including bisphosphonates, teriparatide, denosumab, tamoxifen, or raloxifene. Participants had one follow-up whole-body and site-specific DXA of the lumbar spine and hip performed with a DXA machine from the same manufacturer (ie, Hologic or Lunar) that produced comparable/medication history and administered questionnaires to obtained data on substance use and physical activity. Each participant provided written informed consent. The study was approved by each site’s institutional review board.

HIV-Uninfected Controls

For comparison to HIV-infected individuals, we gained access to participant-level data from 2 longitudinal studies, which performed DXA in young men and women. DXA data from baseline and year 7 of follow-up were obtained for 692 HIV-uninfected men enrolled in the Boston Area Community Health/Bone Survey [7]. In the metabolic substudy of the Women’s Intergender HIV Study (WIHS), DXA was performed at baseline and year 5 of follow-up in 122 HIV-uninfected women [8]. We excluded data from participants in these studies who were outside the sex-specific age window of HIV-infected participants (the age of HIV-infected men and women at initial DXA was 20–64 years and 23–55 years, respectively) and assumed a linear rate of change in BMD among HIV-uninfected individuals.

Received 15 March 2016; accepted 9 May 2016.


Correspondence: P. M. Grant, Division of Infectious Diseases and Geographic Medicine, Stanford University, 300 Pasteur Dr, Rm S-101, Stanford, CA 94305-5107 (pgrant@stanford.edu).

The Journal of Infectious Diseases®
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com.
DOI: 10.1093/infdis/jiw204
Statistical Analyses
We used repeated measures analyses with piecewise slopes to compare the rate of change, calculated as the percentage change in BMD per year, in lumbar spine and hip BMD between HIV-infected and uninfected individuals during the first 96 weeks of study (hereafter, the early period) and from 96 weeks to the end of study follow-up (hereafter, the late period), adjusting for age, sex, race, body mass index (BMI), self-reported physical activity level, cigarette and alcohol use, and receipt of relevant concomitant medications. We analyzed concomitant medications as 2 variables: medications that may increase BMD (ie, testosterone, calcium, vitamin D, hormone replacement, and parathyroid hormone) and those that may decrease BMD (ie, corticosteroids, hormonal contraceptives, anti–hepatitis C virus medications, anticonvulsants, selective serotonin uptake inhibitors, and proton pump inhibitors).

In HIV-infected individuals, we compared rate of change in BMD during the early period to that in the late period and performed multivariable analyses to examine associations during both the early and late periods between the rate of change in BMD and age, sex, race, baseline body mass index (BMI), randomized ART regimen, cumulative TDF and protease inhibitor (PI) exposure, and baseline and time-updated total lean body mass, receipt of relevant concomitant medications, CD4+ T-cell count, and HIV RNA level.

Factors with univariate P values of <.20 were included in multivariable models, which used backward selection and retained factors with P values of <.05. Analysis was 2-sided with a type 1 error of 5%; thus, P values of <.05 were considered statistically significant without adjustment for multiple comparisons.

RESULTS

Patient Characteristics
Ninety-seven of 269 participants from ACTG A5224s enrolled in this study. Baseline characteristics between ACTG A5224s participants who were and those who were not enrolled in this study did not differ significantly. Briefly, among ACTG A5224s participants who were and those who were not enrolled, the median age at enrollment in ACTG A5224s was 40 years and 38 years, respectively; the proportion of males was 86% and 85%, respectively; and the median baseline CD4+ T-cell count was 247 cells/µL and 229 cells/µL, respectively (P > .05 for all comparisons).

Characteristics of HIV-infected participants and HIV-uninfected controls differed; HIV-infected individuals were younger, had a lower BMI at both initial and final DXA, and had higher rates of never smokers and individuals reporting low-to-moderate alcohol consumption (Table 1). Median time between initial and final DXA in HIV-infected participants and controls was 7.6 years (interquartile range [IQR], 7.3–7.8 years) and 6.9 years (IQR, 6.5–7.3 years), respectively.

Among HIV-infected participants, median age at initial DXA was 40 years (vs 46 years among uninfected individuals; P < .001). Eighty-six percent of participants were male (vs 87% of uninfected
individuals; \( P = .62 \). Median CD4\(^+\) T-cell count at initial and final DXA was 247 cells/µL and 598 cells/µL, respectively. Median HIV RNA level at initial DXA was 4.6 log\(_{10}\) copies/mL, and 86% of participants had an HIV RNA level of <200 copies/mL at final DXA. The median duration of TDF exposure during study follow-up was 5.8 years, and the median duration of PI exposure was 3.7 years. Seventy-one percent of HIV-infected participants were receiving TDF, and 45% were receiving a ritonavir-boosted PI at final DXA.

**Rate of Change in BMD in HIV-Infected Individuals Versus That in Controls During the Early Period**

Supplementary Figure 1A displays the unadjusted rate of change in BMD in HIV-infected and HIV-uninfected individuals at the lumbar spine over the study period. After adjustment, HIV-infected individuals had a greater rate of decline in lumbar spine BMD during the early period (ie, from initial DXA to 96 weeks), compared with HIV-uninfected individuals (~0.76%/year vs 0.09%/year; 95% confidence interval [CI] for the difference, ~1.34%/year to ~0.37%/year; \( P = .001 \)).

Supplementary Figure 1B shows the unadjusted rate of change in hip BMD, by serostatus. HIV-infected individuals had greater adjusted rate of decline in hip BMD during the early period, compared with HIV-uninfected individuals (~1.56%/year vs ~0.31%/year; 95% CI for the difference, ~1.71% to ~.80%; \( P < .001 \)).

**Rate of Change in BMD in HIV-Infected Individuals Versus That in Controls During the Late Period**

There was a trend toward a slowing rate of decline in lumbar spine BMD in HIV-infected individuals between the early and late periods (~0.76%/year vs ~0.25%/year; 95% CI for the difference, ~1.08% to ~0.06%; \( P = .08 \)). However, HIV-infected individuals continued to have a greater adjusted rate of decline in lumbar spine BMD during the late period, compared with uninfected individuals (~0.25%/year vs 0.09%/year; 95% CI for the difference, ~0.60%/year to ~0.09%/year; \( P = .008 \)).

Between the early and late periods, the rate of decline in hip BMD in HIV-infected individuals slowed (~1.56%/year vs ~0.31%/year; 95% CI for the difference, ~1.80%/year to ~7.1%/year; \( P < .001 \)). There was no difference in the rate of change in hip BMD between HIV-infected individuals and uninfected individuals during the late period (~0.31%/year vs ~0.31%/year; 95% CI for the difference, ~23%/year to ~23%/year; \( P = .99 \)).

### Factors Associated With Changes in BMD in HIV-Infected Individuals During the Early Period

During the early period, randomization to TDF/FTC arm, lower baseline and time-updated CD4\(^+\) T-cell count, and higher baseline HIV RNA level were associated with greater BMD loss at the lumbar spine (Table 2; \( P = .045, P < .001, P = .005, \) and \( P < .001 \), respectively). In multivariable analysis, randomization to TDF/FTC arm, lower baseline CD4\(^+\) T-cell count, and higher HIV RNA level remained associated with greater BMD loss at the lumbar spine (\( P = .028, P = .005, \) and \( P = .029 \), respectively).

Time-updated total lean body mass and time-updated receipt of concomitant medications that decrease BMD were associated with a change in BMD at the hip during the early period (\( P = .001 \) and \( P = .03 \), respectively; Table 3). Both factors remained statistically significant in multivariable analysis (\( P = .001 \) and \( P = .03 \), respectively).

### Factors Associated With Changes in BMD in HIV-Infected Individuals During the Late Period

During the late period, in univariate analyses, female sex and lower baseline and time-updated total lean body mass were associated with greater decreases in lumbar spine BMD (\( P = .011, P = .003, \) and \( P < .001 \), respectively). In multivariable analysis,
only lower time-updated total lean body mass was significantly associated with greater BMD loss at the lumbar spine (P < .001).

In univariate analyses for changes in hip BMD during the late period, baseline receipt of concomitant medications that lower BMD, baseline HIV RNA level, and time-updated total lean body mass were associated with a change in hip BMD (P = .001, P = .03, and P < .001, respectively). In multivariable analysis, receipt of concomitant medications that lower BMD and time-updated total lean body mass remained associated with a change in hip BMD (P < .001 for both). There was no relationship between HIV-related or treatment-related factors and BMD loss at the lumbar spine or hip during the late period.

**DISCUSSION**

Few studies have evaluated long-term BMD changes in HIV-infected individuals after ART initiation. Most studies have been limited to 96 weeks [4, 5]. Longer-term BMD changes from Gilead 903 were reported, but the study lacked an HIV-infected control group [9]. Controlled studies include HIV-infected individuals already receiving ART at study initiation. Most studies have been limited to 96 weeks [4, 5]. Longer-term BMD changes have been evaluated in a study of HIV-infected individuals [8, 12]. We found no relationship between cumulative TDF or PI exposure and BMD decline during the late period. Several studies have shown that BMD increases after a switch from TDF to an alternative agent [13, 14]. However, our study suggests that, after the initial independent negative impact of TDF, there may not be continued BMD decrease attributable to TDF. Our data are reassuring in that even with Food and Drug Administration approval of tenofovir alafenamide, TDF likely will remain commonly used for HIV treatment in resource-limited settings (at least in the near future) and for preexposure prophylaxis globally.

There are several limitations to our study. Control populations were not specifically recruited for our study; unmeasured factors could account for differences in the rate of decline in BMD between the HIV-infected and control groups. Many ACTG A5224s participants were not enrolled in this study; however, similar baseline characteristics between those who were and those who were not enrolled provide reassurance that this is unlikely to be a major source of bias. We lacked complete data on covariates, such as hepatitis C virus infection, testosterone level, and vitamin D level, that could affect BMD. In the control population, spine BMD slightly increased, but this is consistent with what has been reported in other studies [15]. The difference in the rate of change in BMD between HIV-infected and uninfected controls was statistically significant (P < .001 for both).

**Table 3. Univariate and Multivariable Associations With Percentage Change in Total Hip Bone Mineral Density Among Human Immunodeficiency Virus (HIV)-Infected Participants**

<table>
<thead>
<tr>
<th>Interval, Covariate</th>
<th>Univariate Analysis</th>
<th>Multivariable Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Percentage Change/Year (95% CI)</td>
<td>P Value</td>
</tr>
<tr>
<td>Initial to week 96</td>
<td>. . .</td>
<td>. . .</td>
</tr>
<tr>
<td>Time-updated lean body mass (per 1 kg higher)</td>
<td>0.08 (0.03–1.12)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Time-updated use of medications that lower BMD vs those that do nota</td>
<td>0.68 (0.07–1.30)</td>
<td>.03</td>
</tr>
<tr>
<td>Week 96 to final</td>
<td>. . .</td>
<td>. . .</td>
</tr>
<tr>
<td>Time-updated lean body mass (per 1 kg higher)</td>
<td>0.06 (0.03–0.09)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Baseline use of medications that lower BMD vs those that do nota</td>
<td>0.72 (0.29–1.34)</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Baseline HIV RNA load (per 1 log10 copy/mL higher)</td>
<td>0.44 (0.05–0.84)</td>
<td>&lt; .001</td>
</tr>
</tbody>
</table>

Only associations with a P value of <.05 are displayed. Data were evaluated for associations between bone mineral density change and age, sex, baseline body mass index, randomized antiretroviral regimen, cumulative tenofovir disoproxil fumarate and protease inhibitor exposure, and baseline and time-updated total lean body mass, receipt of relevant concomitant medications, CD4+ T-cell count, and HIV RNA level. Abbreviations: BMD, bone mineral density; CI, confidence interval.

a Defined as receipt of corticosteroids, hormonal contraceptives, hepatitis C medications, anticonvulsants, selective serotonin uptake inhibitors, or proton pump inhibitors.
infected individuals and uninfected individuals is relatively modest. However, the increased loss could be compounded in persons with preexisting low BMD or if the loss continues beyond the evaluated period. HIV-infected individuals reported high physical activity levels; BMD loss may be greater in sedentary individuals. ART has evolved since this study was completed. Whether our results would extend to individuals receiving newer antiretrovirals is unknown. We did not have complete data on ART interruptions, although there were high levels of adherence with ART at final DXA.

In conclusion, we found that HIV-infected individuals continue to lose BMD after the rapid decline during the first 2 years of ART, albeit at a slower rate. BMD loss in HIV-infected individuals remains greater than in uninfected controls at the lumbar spine but not at the hip through 7.5 years after ART initiation. Low lean body mass is a consistent predictor of BMD loss in long-term treated individuals. Fragility fractures may increase as HIV-infected individuals continue to receive ART for decades, and interventions to maintain or increase lean body mass may benefit long-term skeletal health.

**Supplementary Data**

Supplementary materials are available at http://jid.oxfordjournals.org. Consisting of data provided by the author to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the author, so questions or comments should be addressed to the author.

**Notes**

**Disclaimer.** The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Allergy and Infectious Diseases (NIAID) or the National Institutes of Health (NIH).

**Financial support.** This work was supported by the NIAID (award U01AI068636), the National Institute of Mental Health (NIMH), and the National Institute of Dental and Craniofacial Research (NIDCR), the NIH (grants K23AI108358, UM1AI069481, UM1AI069494, K23AG050260, R01AG020727, U01AI042590, and K24AI120834), Gilead Sciences, and Viiv Healthcare. Additionally, data in this manuscript were collected by 3 R01AG020727, U01AI042590, and K24AI120834), Gilead Sciences, and (grants K23AI108358, UM1AI069481, UM1AI069494, K23AG050260, R01AG020727, U01AI042590, and K24AI120834), Gilead Sciences, and Viiv Healthcare. Additional data in this manuscript were collected by 3 sites of the Women’s Interagency Human Immunodeficiency Virus Study (WHIS): the Bronx WHIS (principal investigator Kathryn Anastas; supported NIH grant U01-AI-035004), the Chicago WHIS (principal investigators Mardge Cohen and Audrey French), and the Connie Wofsy Women’s HIV Study, Northern California (principal investigators Ruth Greenblatt, Bradley Aouizerat, and Phyllis Tien). The WHIS is funded primarily by the NIAID, with additional cofunding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development, the National Cancer Institute, the National Institute on Drug Abuse, and the NIMH. Targeted supplemental funding for specific projects is also provided by the NIDCR, the National Institute on Alcohol Abuse and Alcoholism, the National Institute on Deafness and other Communication Disorders, and the NIH Office of Research on Women’s Health.

**Potential conflicts of interest.** P. M. G. has received grant support (paid to the institution) from Bristol-Myers Squibb, Gilead Sciences, Janssen Pharmaceuticals, and Viiv Healthcare. G. A. M. has been a consultant for Bristol-Myers and Gilead Sciences and received grant support (paid to the institution) from Bristol-Myers Squibb, Gilead Sciences, and Viiv Healthcare. A. C. C. is a former member of a data safety monitoring board for a study sponsored by Merck and has received grant support (paid to the institution) from Bristol-Myers Squibb. S. L. K. has received grant support (paid to the institution) from Gilead Sciences. K. M. E. has received grant support (paid to the institution) from Gilead Sciences and Janssen Pharmaceuticals. M. T. Y. has served as a consultant for Gilead Sciences and B. H. is an employee of Viiv Healthcare. K. M. is an employee of Gilead Sciences. T. T. B. has served as a consultant for Abbott Laboratories, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Merck, and Viiv Healthcare. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**


BRIEF REPORT • JID • 5